We confirmed that relative to those with LGR5+ and KRASmut status, LGR5−/KRASwt colon carcinomas had decreased CDH1 and increased VIM and SLUG expressions, which are the expected changes in EMT biomarkers (Figure 6J). This evidence concerns the gene LGR5 and colon carcinoma.